Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of
View HTML
Toggle Summary Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi)
View HTML
Toggle Summary Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 29, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018 , the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for an adaptive Phase 2/3 trial with the potential to serve as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 1, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Barclays Global Healthcare Conference 2019 – Miami , March 12-14, 2019 March 12 , 4:20 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Feb. 7, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for
View HTML